Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Apr 16;47(5):100721. doi: 10.1016/j.bj.2024.100721

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 4 — Assessment of the intravenous administration of ^99mTc-UCMSC-EVs and comparison with ^99mTc-NaTcO4. (a) In vivo SPECT/CT fused representative images of ^99mTc-UCMSC-EVs and Na^99mTcO4 at various time points postinjection. Significant uptake of ^99mTc-UCMSC-Evs was found in the liver, spleen, lung, and bone. The elimination route of ^99mTc-UCMSC-EVs was shown to be through the urinary tract. Furthermore, there was no observed uptake in the thyroid and stomach for the ^99mTc-UCMSC-EVs group compared with the Na^99mTcO4 group, indicating that the ^99mTc-UCMSC-EVs were stable in vivo. (b) Quantification of ^99mTc-UCMSC-EVs in organs/tissues of interest at various time points postinjection. The spleen uptake of ^99mTc-UCMSC-EVs 24 h postinjection was significantly elevated compared with that at previous time points (67.57 ± 10.65%ID/g, ∗). No ^99mTc-UCMSC-EVs were observed in the kidney, lung, bone, spine, or bladder. ∗, p < 0.05.